Form 4 for IOVA IOVANCE BIOTHERAPEUTICS, INC.
Accepted 2025-05-16 00:00:00 ET · period of report 2025-05-14 · accession 0001104659-25-049999 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | 2025-05-14 | IOVA | Vogt Frederick G | GC, Interim CEO, Dir | P - Purchase | $1.69 | +25.0K | 374.6K | +7% | +$42.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-14 | P | A | 25,000 | $1.69 | 374,646 | D | — | — | (F1) Shares were acquired in the open market during a permitted trading window in accordance with the Issuer's Insider Trading Policy. A copy of the Insider Trading Policy is filed as Exhibit 19.1 to the Issuer's Annual Report on Form 10-K for the year ended December 31, 2024. |